» Articles » PMID: 29376447

Characterizing Disease-associated Changes in Post-translational Modifications by Mass Spectrometry

Overview
Publisher Informa Healthcare
Date 2018 Jan 30
PMID 29376447
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Exploring post-translational modifications (PTMs) with the use of mass spectrometry (PTMomics) is a rapidly developing area, with methods for discovery/quantification being developed and advanced on a regular basis. PTMs are highly important for the regulation of protein function, interaction and activity, both in physiological and disease states. Changes in PTMs can either cause, or be the result of a disease, making them central for biomarker studies and studies of disease pathogenesis. Recently, it became possible to study multiple PTMs simultaneously from low amount of sample material, thereby increasing coverage of the PTMome obtainable from a single sample. Thus, quantitative PTMomics holds great potential to discover biomarkers from tissue and body fluids as well as elucidating disease mechanisms through characterization of signaling pathways. Areas covered: Recent mass spectrometry-based methods for assessment of the PTMome, with focus on the most studied PTMs, are highlighted. Furthermore, both data dependent and data independent acquisition methods are evaluated. Finally, current challenges in the field are discussed. Expert commentary: PTMomics holds great potential for clinical and biomedical research, especially with the generation of spectral libraries of peptides and PTMs from individual patients (permanent PTM maps) for use in personalized medicine.

Citing Articles

Diverse perspectives on proteomic posttranslational modifications to address EGFR-TKI resistance in non-small cell lung cancer.

Ma Y, Zhang F, Li J, Li J, Li Y Front Cell Dev Biol. 2025; 12():1436033.

PMID: 39777265 PMC: 11703921. DOI: 10.3389/fcell.2024.1436033.


A Tutorial Review of Labeling Methods in Mass Spectrometry-Based Quantitative Proteomics.

Wang Z, Liu P, Li L ACS Meas Sci Au. 2024; 4(4):315-337.

PMID: 39184361 PMC: 11342459. DOI: 10.1021/acsmeasuresciau.4c00007.


Progress in Core-Shell Magnetic Mesoporous Materials for Enriching Post-Translationally Modified Peptides.

Zhu Z, Fu H, Zhao Y, Yan Q J Funct Biomater. 2024; 15(6).

PMID: 38921532 PMC: 11205187. DOI: 10.3390/jfb15060158.


Proteomic Insights into Osteoporosis: Unraveling Diagnostic Markers of and Therapeutic Targets for the Metabolic Bone Disease.

Wang J, Xue M, Hu Y, Li J, Li Z, Wang Y Biomolecules. 2024; 14(5).

PMID: 38785961 PMC: 11118602. DOI: 10.3390/biom14050554.


Multi-omics integration of scRNA-seq time series data predicts new intervention points for Parkinson's disease.

Mihajlovic K, Ceddia G, Malod-Dognin N, Novak G, Kyriakis D, Skupin A Sci Rep. 2024; 14(1):10983.

PMID: 38744869 PMC: 11094121. DOI: 10.1038/s41598-024-61844-3.